Nexalin Technology Issues U.S. Patent for Dynamic Frequency Stimulation Targeting Anxiety, Depression, and Insomnia
Nexalin Technology has been granted a new U.S. patent covering its dynamic frequency stimulation method used to treat anxiety, depression, and insomnia. The patent is expected to provide intellectual property protection through 2042, reinforcing Nexalin's competitive position in non-invasive neurostimulation.
Topics: intellectual_property mental_health neurostimulation